Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent

Fineline Cube Jan 16, 2026
Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Fineline Cube Jan 15, 2026
Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Fineline Cube Jan 15, 2026
Company Deals

Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy

Fineline Cube Jan 15, 2026
Company Deals

WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development

Fineline Cube Jan 15, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan‑TEAD Inhibitor for Solid Tumors

Fineline Cube Jan 16, 2026
Company Drug

Vitalgen’s VGN‑R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease

Fineline Cube Jan 16, 2026
Company Legal / IP

Amgen Inc. Reports 7% YOY Revenue Increase in Q2 2023 Financials

Fineline Cube Aug 4, 2023

US-based biotechnology company Amgen Inc., (NASDAQ: AMGN) has released its financial results for the second...

Company Legal / IP

GSK Files Patent Infringement Lawsuit Against Pfizer’s RSV Vaccine Abrysvo

Fineline Cube Aug 4, 2023

UK pharmaceutical giant GlaxoSmithKline (NYSE: GSK) has taken US-based Pfizer Inc., (NYSE: PFE) to court,...

Company Deals

Novartis AG and Ionis Pharmaceuticals Renew Collaboration on Lp(a)-Driven CVD Drug

Fineline Cube Aug 4, 2023

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has returned to US-based Ionis Pharmaceuticals Inc., (NASDAQ:...

Company Drug

Grand Pharmaceutical Group Gets NMPA Approval for Generic Eplerenone for Hypertension

Fineline Cube Aug 4, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that it has received marketing approval...

Company Deals

Chia Tai Tianqing Secures Exclusive Rights to InventisBio’s D-1553 in China Licensing Deal

Fineline Cube Aug 4, 2023

China-based Chia Tai Tianqing has signed a licensing agreement with compatriot firm InventisBio, securing exclusive...

Company Medical Device

DaVinci Single Port System Launches in Hainan with Successful Surgeries

Fineline Cube Aug 4, 2023

The DaVinci Single Port robot-assisted surgical system technology has been successfully implemented in Boao, Hainan...

Policy / Regulatory

Shanghai’s SMPA Reduces Ceiling Price for Non-Winning Bids in Artificial Joint VBP Tender

Fineline Cube Aug 4, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has issued a notification regarding an artificial joint volume-based...

Company Deals

Kunshan Yiyuan Medical Technology Secures Over RMB 100 Million in Series B Financing

Fineline Cube Aug 4, 2023

Kunshan Yiyuan Medical Technology Co., Ltd (Medical Source), a company in China that specializes in...

Company Deals

HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max

Fineline Cube Aug 4, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced a licensing agreement with fellow Shanghai-based firm...

Company

Novartis China’s Business Growth Lead Zhu Jiakang Departs for Personal Reasons

Fineline Cube Aug 4, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has seen the departure of Zhu Jiakang, who led...

Company

BeiGene’s Q2 2023 Financial Report Highlights 81.8% YOY Product Revenue Growth

Fineline Cube Aug 3, 2023

China-based biotech company BeiGene (SHA: 688235, HKG: 6160, NASDAQ: BGNE) has released its financial report...

Legal / IP Policy / Regulatory

National Health Commission’s Anti-Corruption Drive Impacts China’s Pharmaceutical Sector

Fineline Cube Aug 3, 2023

An anti-corruption crackdown announced by the National Health Commission (NHC) at the end of July...

Company Medical Device

Our United Corporation’s Linear Accelerator Approved as Innovative Medical Device by NMPA

Fineline Cube Aug 3, 2023

Xi’an-based Our United Corporation has announced that its medical electronic linear accelerator has been approved...

Company Drug

CORXEL Gets CDE Approval for Phase III Presbyopia Trials of LNZ100 and LNZ101

Fineline Cube Aug 3, 2023

Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has announced that...

Company Deals

Lee’s Pharmaceutical Subsidiary Zhaoke Ophthalmology Partners with Eyebright Medical Technology

Fineline Cube Aug 3, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has entered...

Company Deals

BeiGene and Bristol-Myers Squibb/Celgene Settle Partnership, Termination Set for 2023

Fineline Cube Aug 3, 2023

BeiGene (NASDAQ: BGNE) has announced a settlement and termination agreement with US firm Bristol-Myers Squibb/Celgene...

Company Medical Device

Suzhou Jiecheng Medical Secures FDA BDD for Transvascular Aortic Valve Treatment

Fineline Cube Aug 3, 2023

Suzhou Jiecheng Medical Technology Co., Ltd has announced that it has obtained Breakthrough Devices Designation...

Company Drug

ABM Therapeutics’ ABM-1310 Earns Orphan Drug Designation for BRAF V600 Mutant Glioblastoma

Fineline Cube Aug 3, 2023

Shanghai-based ABM Therapeutics Inc. has announced that it has received Orphan Drug Designation (ODD) from...

Company Deals

Huaboron Neutron Technology Secures Over RMB 100 Million in Angel Financing for BNCT System

Fineline Cube Aug 3, 2023

Huaboron Neutron Technology (Hangzhou) Co., Ltd (HBNCT) has reportedly secured more than RMB 100 million...

Company Deals

ICE Bioscience Secures Series B+ Financing to Boost Integration Capabilities

Fineline Cube Aug 3, 2023

Beijing-based Contract Research Organization (CRO) ICE Bioscience has reportedly raised close to RMB 100 million...

Posts pagination

1 … 437 438 439 … 610

Recent updates

  • Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan‑TEAD Inhibitor for Solid Tumors
  • Vitalgen’s VGN‑R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease
  • Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent
  • Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal
  • Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan‑TEAD Inhibitor for Solid Tumors

Company Drug

Vitalgen’s VGN‑R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease

Company Deals

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.